Author:
Berenson J R,Yellin O,Kazamel T,Hilger J D,Chen C-S,Cartmell A,Woliver T,Flam M,Bravin E,Nassir Y,Vescio R,Swift R A
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference37 articles.
1. Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526.
2. Kumar SK, Rajkumar V, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.
3. Kumar S, Flinn IW, Richardson PG, Hari P, Callander NS, Noga SJ et al. Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized phase 2 EVOLUTION study. Blood 2010; 116, abstract 621.
4. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530–1534.
5. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136–1144.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献